BioSpace News Archive

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”), today announced that two abstracts featuring targeted radiotherapies in combination with CD47 antibody immunotherapy for solid tumor and hematologic indications have been accepted for presentation at the 36th Annual Meeting of the Society for Immunotherapy for Cancer (SITC 2021).

The Food and Drug Administration’s Office of Counterterrorism and Emerging Threats has awarded a contract worth over $1.78M to Siemens Government Technologies with technology from Siemens Digital Industries.

NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that new data from two clinical studies and one research study will be presented during oral and poster sessions at the Society for Immunotherapy of Cancer (SITC) annual meeting, to be held in Washington, D.C.,

Citius Pharmaceuticals, Inc. announced that Citius Executive Chairman Leonard Mazur and his wife, Helena Mazur, were honored by Temple University, Philadelphia, PA, which renamed the main building housing the College of Liberal Arts to Leonard and Helena Mazur Hall in recognition of the Mazur’s longstanding commitment to Temple University’s students and alumni.

Anixa Biosciences, Inc. (NASDAQ: ANIX) (“Anixa”), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance broadening protection of Anixa’s novel Chimeric Antigen Receptor-T cell (CAR-T) cancer treatment technology, known as its Chimeric Endocrine Receptor T-cell,

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced oral and poster presentations of clinical and non-clinical data for tumor infiltrating lymphocyte (TIL) cell therapies in multiple solid tumors will be presented at the 36thAnnual Meeting of the Society for Immunotherapy of Cancer (SITC).

Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, today announced it will have two poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 2021 Annual Meeting, taking place from November 10-14, 2021.

Alpha Cognition Inc. announced the formation of a Scientific Advisory Board comprised of industry leaders in neurology and psychiatry, chaired by James E. Galvin, MD, MPH.

Transgene (Euronext Paris: TNG) (Paris:TNG), and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), today announce that they will present additional preclinical data on their novel dual mechanism-of-action oncolytic vaccinia virus BT-001 at the 36th Annual Meeting of the Society for Immunotherapy of Cancer.

Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, today announced it has submitted all the planned modules as well as a risk management plan and pediatric investigation plan for the lenzilumab Conditional Marketing Authorization (CMA) in hospitalized COVID-19 patients to the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA).